source
- STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreNovartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deathsSTAT · 19h ago↗ source
- Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 1d ago↗ source
- Recent heart-drug trials miss endpoints, raising doubts about AI-driven drug designTwo large clinical studies presented at the American Heart Association meeting this weekend failed to show any benefit for experimental heart‑attack and stroke therapies, underscoring the difficult…